Skip to Main content Skip to Navigation
New interface
Journal articles

Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B

Abstract : Botulinum neurotoxins (BoNTs) are responsible for human botulism, a life-threatening disease characterized by flaccid muscle paralysis that occurs naturally by food poisoning or colonization of the gastrointestinal tract by BoNT-producing clostridia. BoNTs have been classified as category A agents by the Centers for Disease Control and Prevention. To date, 7 subtypes of BoNT/B were identified showing that subtypes B1 (16 strains) and B2 (32 strains) constitute the vast majority of BoNT/B strains. Neutralizing antibodies are required for the development of anti-botulism drugs to deal with the potential risk. In this study, macaques (Macaca fascicularis) were immunized with recombinant light chain (LC) or heavy chain (HC) of BoNT/B2, followed by the construction of 2 hyper-immune phage display libraries. The best single-chain variable fragments (scFvs) isolated from each library were selected according to their affinities and cross reactivity with BoNT/B1 toxin subtype. These scFvs against LC and HC were further analyzed by assessing the inhibition of in vitro endopeptidase activity of BoNT/B1 and B2 and neutralization of BoNT/B1 and B2 toxin-induced paralysis in the mouse ex vivo phrenic nerve assay. The antibodies B2-7 (against HC) and BLC3 (against LC) were produced as scFv-Fc, and, when tested individually, neutralized BoNT/B1 and BoNT/B2 in a mouse ex vivo phrenic nerve assay. Whereas only scFv-Fc BLC3 alone protected mice against BoNT/B2-induced paralysis in vivo, when B2-7 and BLC3 were combined they exhibited potent synergistic protection. The present study provided an opportunity to assess the extent of antibody-mediated neutralization of BoNT/B1 and BoNT/B2 subtypes in ex vivo and in vitro assays, and to confirm the benefit of the synergistic effect of antibodies targeting the 2 distinct functional domains of the toxin in vivo. Notably, the framework regions of the most promising antibodies (B2-7 and BLC3) are close to the human germline sequences, which suggest that they may be well tolerated in potential clinical development.
Document type :
Journal articles
Complete list of metadata

Cited literature [68 references]  Display  Hide  Download
Contributor : Floran Bidault Connect in order to contact the contributor
Submitted on : Wednesday, May 2, 2018 - 2:03:08 PM
Last modification on : Thursday, April 7, 2022 - 10:10:24 AM
Long-term archiving on: : Tuesday, September 25, 2018 - 10:02:06 AM


Development of human like scFv...
Publication funded by an institution


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License




Christine Rasetti-Escargueil, Arnaud Avril, Siham Chahboun, Rob Tierney, Nicola Bak, et al.. Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B. mAbs, 2015, 7 (6), pp.1161 - 1177. ⟨10.1080/19420862.2015.1082016⟩. ⟨pasteur-01783494⟩



Record views


Files downloads